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Abstract With increased innovation and development of
specialty pharmaceuticals, the US and global healthcare
industries are looking to implement appropriate manage-
ment strategies to control both utilization and costs. Spe-
cialty pharmaceuticals are high-cost medications that treat
complex, chronic, rare, and difficult-to-manage conditions.
These drugs require special drug handling, appropriate
clinical outcomes monitoring, and effective cost controls.
The primary scope of this article is to discuss various
strategies being implemented for specialty pharmaceutical
utilization and cost management and correlated outcomes
in the USA; these outcomes include enhanced health
insurance plan benefit designs with formulary modifica-
tions and greater patient cost burden. Additional methods
to manage specialty pharmaceuticals include the use of
specialty pharmacies for drug distribution, increased
emphasis on coordination of care and evidence-based
medicine, as well as healthcare reform and regulations.
Healthcare spending, both in the US and globally, contin-
ues to increase, with a rising proportion of drug spend
towards specialty pharmaceuticals. Continued specialty
pharmaceutical innovation and introduction of biosimilar
products will evolve the currently utilized management
strategies for these drugs.
Key Points for Decision Makers
Cost drivers for increased drug spend on specialty
pharmaceuticals include increased utilization,
expanded indications, and the introduction and
development of new biologic agents.
Key management strategies for specialty
pharmaceuticals include the implementation of
specialty tiers and complex formulary designs, drug
restrictions through prior authorizations and quantity
limits, co-payments and co-insurance rates that
increase patient cost burden, specialty pharmacy
provider use for drug distribution, medication therapy
management programs to increase coordination of
care, quality measures enforced through healthcare
reform and accountable care organizations, increased
use of evidence-based medicine, and government
regulation for biosimilars and price controls.
Continued development of specialty pharmaceuticals
in the biopharmaceutical industry pipeline, primarily
targeting orphan diseases, oncology, hepatitis C,
inflammatory conditions, multiple sclerosis, and
HIV, coupled with the introduction of biosimilars,
will affect the cost impact of these drugs and evolve
drug utilization and cost-management strategies.
1 Background on Specialty Pharmaceuticals
1.1 Definition of Specialty Pharmaceuticals
The development and utilization of specialty pharmaceu-
ticals have significantly impacted global healthcare
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practices and costs. Although the development of, and
healthcare spending on, specialty pharmaceuticals has
increased over the last decade, a universally accepted
definition remains undetermined. Characteristically, a
specialty pharmaceutical treats a complex, chronic, rare,
and difficult-to-manage condition and may include blood
derivatives or bioengineered proteins. Administration of
specialty drugs is typically via injection or infusion in the
physician’s office or via self-injection; however, some
specialty drugs may be orally administered. These bio-
pharmaceutical drugs may require special handling, such as
refrigeration or radiation shielding and typically need
ongoing monitoring for efficacy, safety, and an overall
positive clinical response [1, 2]. According to the 2010
Healthcare Distribution Management Association (HDMA)
study of specialty pharmaceutical distributors, on average,
specialty drugs account for 49 % of all pharmaceuticals
that necessitate risk evaluation and mitigation strategies
(REMS) [3]. Specialty pharmaceuticals are often high-cost
prescription drugs, ranging from several hundred to thou-
sands of dollars, with some regimens costing up to
$US10,000 per month [1, 3–5]. For example, according to
the Centers for Medicare and Medicaid Service (CMS) Part
D drug benefit, a specialty drug is categorized as one with a
minimum monthly cost of $US600. Some insurance plans
also set cost thresholds, which can be up to double this
amount. Through survey information, 84 % of commercial
payers classify a specialty pharmaceutical based on the
cost, with $US1,154 determined as the average minimum
monthly cost [1]. The term ‘specialty pharmaceuticals’ is
sometimes used interchangeably with ‘biologic drugs’;
however, it is important to note that not all specialty drugs
are biologic products (e.g. sofosbuvir, a small molecule for
hepatis C) and not all biologic products are considered
specialty drugs (e.g. insulin) [4, 5].
1.2 Scope and Cost of Specialty Drugs
For the scope of this review article, case examples and
outcomes from specialty pharmaceutical utilization strate-
gies aimed to reduce cost are focused primarily in the US
due to the diversity and complexities across its health
system. A subsequent review focusing on non-US
approaches when there is greater governmental involve-
ment as a payer rather than diverse private and public
insurance plans would be warranted since the rising costs
of specialty drugs is a global problem. Some examples are
presented from EU data, particularly related to the appli-
cation of cost-effectiveness analysis and biosimilar pre-
scribing since there is more information from the EU in
these endeavors.
Overall US healthcare spending, which encompasses
hospitalizations, physician office visits, and prescriptions
filled, continues to rise. Approximately 11 % of healthcare
costs are related to prescription medications [6, 7]. In the
USA in 2013, prescription drug expenditure was $US329.2
billion. Spending for specialty drugs and biologic medi-
cations has increased more significantly than the spending
for traditional small molecules. In 2013, specialty medi-
cations in the retail, mail, and non-retail (i.e., long-term
care, institutional) settings accounted for 29 % of spending
on medicines. Spending on biologics increased 9.6–28 %,
whereas the spending for small molecules increased by
0.1 %, accounting for 72 % of drug expenditure [8–10].
Five of the top ten drugs by US sales in 2013 are specialty
drugs. They account for sales in excess of $US21.1 billion.
Four of these drugs are indicated for inflammatory condi-
tions; one for supportive care of malignancies [11].
Inflammatory diseases, multiple sclerosis (MS), and
oncology care accounted for 60 % of the spending on
specialty drugs [12]. From 2012 data, commercial health
plans exhausted more than 90 % of their total specialty
drug spend on approximately 5 % of enrollees. However,
the total specialty drug spend is only 11–12 % of total drug
spending, which accounts for approximately 20–24 % of
overall commercial health plan spending [13].
Global medication sales are expected to exceed $US1
trillion in 2014. The impact of rising costs of specialty
drugs is a global concern. Over the next 5 years, spending
on traditional pharmaceuticals is expected to increase only
5 % in major markets, whereas it is estimated to increase
69 % in emerging markets primarily due to the burden of
chronic disease and higher volume demand for small-
molecule medicines. Through 2017, the developed coun-
tries are estimated to have a 30 % increase in specialty
pharmaceutical spend compared with a 90 % increase in
emerging markets. The emerging markets currently have a
much lower baseline since these markets are not as highly
penetrated, with decreased access and affordability for
specialty pharmaceuticals [9, 10].
Through 2018, a total of 39 specialty products will face
patent expirations, creating opportunities for $US13.1 bil-
lion in specialty generic drugs. Additionally, through 2010,
a total of 51 biologic products will encounter patent expi-
rations, leading to a potential $US31.8 billion market for
biosimilars.
In 2013 alone, 36 new molecular entities (NMEs) were
brought to market, including ten cancer drugs and 17
orphan drugs; of these 36 entities, 20 were specialty drugs
[9]. Additional drug development is expected from a robust
specialty pipeline, with numerous expected launches over
the next 5 years. Of this drug pipeline, approximately 36%
are focused on orphan diseases, 17 % on oncology, 14 %
on hepatitis C, 13 % on inflammatory conditions, 11 % on
other conditions, 5 % on MS, and 4 % on HIV [10]. New
innovative products frequently lead to greater utilization
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and expense. For example, Gilead’s sofosbuvir (SovaldiTM)
for hepatitis C costs $US84,000 for a curative 12-week
course of treatment. Reported first quarter sales for 2014
were $US2.3 billion [14].
2 Cost and Utilization Strategies for Specialty
Pharmaceuticals in the USA
2.1 Benefit Design Modifications
Specialty pharmaceutical management should balance the
need for innovative therapies while employing enhanced
benefit design strategies to control unsustainable rising
costs of specialty drugs [1]. This paper will review some
strategies that have been employed to control these
healthcare costs. With new health insurance plan benefit
structures, there has been a shift to an increased cost bur-
den for patients.
2.1.1 Formulary Modifications, Prior Authorization,
Quantity Limits
Both US Government and commercial insurance plans are
modifying benefit designs to better ensure appropriate
medication utilization and cost control. Since 2005, CMS
required formularies to include ‘‘all or substantially all’’
drugs from six protected classes of clinical concern: anti-
convulsants, antidepressants, antineoplastics, antipsychot-
ics, antiretrovirals, and immunosuppressants for the
treatment of transplant rejection. On 6 January 2012, CMS
proposed a rule with aims of reducing costs and protecting
patients from over-utilization that would significantly
impact Medicare beneficiaries. The ruling would have
removed protection for antidepressant and immunosup-
pressant treatments starting in 2015 and remove antipsy-
chotic therapies 1 year later. However, CMS withdrew its
proposal due to vocal opposition [15].
Furthermore, in order to contain costs and maintain
appropriate utilization, Medicare formularies are imple-
menting prior authorizations (PAs), especially on high-cost
biologic agents. PAs require the prescriber to obtain pre-
approval based on the terms set by the pharmacy benefit
plan, which are determined based on clinical need and
therapeutic rationale [16, 17]. Based on data collected from
stand-alone and Medicare Advantage prescription drug
plans, biologic medications with greater coverage and
within a tier of higher cost sharing, such as anemia or
rheumatoid arthritis, were more likely to be associated with
a prior authorization than those on lower cost-sharing tiers,
such as diabetes or oncology drugs [16]. Authorization
techniques may be implemented to limit access to selected
innovative therapies, since many specialty pharmaceuticals
modulate a specific targeted protein and will only benefit a
subset of patients [1].
Due to the development of new therapies for MS,
patients have expanded therapeutic options. Managed care
organizations (MCOs) are using varied strategies to
manage utilization and costs. For example, 58 % of 109
MCOs surveyed implement prior authorizations for MS
specialty therapies. However, use of this strategy may
decrease, since there is little risk of MS medications being
abused. Instead of PAs, several companies are restricting
quantity limits and using restricted pharmacy networks to
prevent inappropriate use. Frequently, 14- to 30-day sup-
ply limits are implemented for many specialty drugs in all
therapy classes, despite that they are used to treat chronic
conditions. Limiting the maximum amount that can be
dispensed to a patient may reduce costs and minimize
waste if doses or treatment regimens are changed [14].
Unfortunately, these policies may adversely impact patient
out-of-pocket (OOP) expenditures due to co-pays and co-
insurance [18].
2.1.2 Complex Formulary Tiers—Co-Payments
vs. Co-Insurance
Cost-containment mechanisms include cost sharing that
increases overall OOP costs for patients. These techniques
involve mandated co-insurance and/or co-payments. The
formulary tier determines the varying costs for co-pay-
ments and co-insurance. Co-pays can be set as flat rates for
all specialty drugs or set based on tiers of preferred and
non-preferred therapeutic agents, while co-insurance is a
defined percentage [2].
Medicare formularies have looked to create tier struc-
tures that are more complex than the two-tier framework
with generic medications on tier 1 and brand medications
on tier 2, and shift a greater cost burden for the patients
through increased cost sharing. This approach is used to
gear providers and patients towards lower cost drugs.
Under Medicare Part D, CMS has designated only one tier
as a specialty tier. Cost sharing in this tier is limited to a
25 % maximum after the deductible and before the initial
coverage limit, or limited to 33 % in plans with decreased
or no deductible under alternative prescription drug cov-
erage designs. The specialty tier is for Part D drugs
exceeding the payer’s negotiated prices of $US600 per
month. The implementation of a specialty tier allows for
lower cost sharing on non-specialty tiers [19].
According to the Kaiser Family Foundation data, the
table below represents the increase in Medicare Part D
Plans (PDPs) that use specialty tiers from 2010 to 2013
[20].
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2010 2011 2012 2013
Percentage of plans with a
specialty tier
84 % 85 % 87 % 90 %
Average number of drugs on
a designated specialty tier
158 171 179 194
Average percentage of drugs
on a designated specialty
tier
4.8 % of all
Part D
drugs
6.4 % 7.8 % 8.6 %
Most top-selling biologics for stand-alone and Medicare
advantage prescription drug plans are on the fourth tier,
which requires the highest level of cost sharing compared
with diabetes medications (i.e., insulin), which are typi-
cally on tiers two or three. For these biologics, co-pay-
ments can reach up to $US60 for a 30-day supply, and co-
insurance is typically 25 % of the drug’s cost, which
increases the patient cost burden for these high-cost med-
ications. However, data from 2006 to 2009 reveal that the
most common co-insurance rate for biologic agents is
33 %, which is an even greater patient cost burden [16, 20].
Commercial health plans in the US typically use a three-
tier benefit structure, with 77 % of covered workers in
plans that have three or more tiers of various cost-sharing
levels. These tiers are designed such that generic drugs are
on the first tier, preferred branded drugs are on the second
tier, non-preferred branded drugs are on the third tier, and
fourth-tier drugs include biologics, specialty pharmaceuti-
cals, and lifestyle drugs. The differentiation between tier 2
and 3 products is based on relative safety, effectiveness,
and cost as determined by the pharmacy benefit plan for
branded drugs without generic substitutes. Three or more
tiers of cost sharing have been implemented more fre-
quently over the past 10 years, with more commercial plans
utilizing co-payments, faced by 55 % of employees, com-
pared with co-insurance applied to 36 % of employees. The
typical co-payment amounts are comparable from 2011 to
2012 at $US10 for first-tier drugs, $US29 for second-tier
drugs, $US51 for third-tier drugs, and $US79 for fourth-tier
drugs. On the other hand, for employees covered by a
commercial plan with more than three tiers who face co-
insurance versus co-payments, the typical average co-
insurance levels are 20 % for first-tier drugs, 26 % for
second-tier drugs, 39 % for third-tier drugs, and 32 % for
fourth-tier drugs. Only 10 % of employees have their
prescription drug benefit through commercial plans with
two tiers, with an average co-payment of $US11 for first-
tier drugs and $US29 for second-tier drugs. For two-tier
plans with co-insurance requirements, the average co-
insurance is 27 % for their second-tier drugs. Only 6 % of
workers have a plan where cost sharing is identical
regardless of the drug, with an average $US13 co-payment
faced by 14 % of this population, and an average 22 %
co-insurance faced by 85 % of this population. A majority
of commercial plans, covering 87 % of workers, limit
employees’ cost sharing with varying OOP maximums. For
example, 41 % of plans have a $US3,000 or higher OOP
maximum, whereas 16 % of plans have a maximum OOP
payment of $US1,500 or less [13].
There is also an increased demand for patient assistance
programs (PAPs) established by pharmaceutical and bio-
pharmaceutical manufacturers, which provide no- or low-
cost medications to those with no insurance or those that
are under-insured. The US Federal Government does not
require PAPs, but manufacturer companies do receive
significant tax breaks. PAPs increase access to medications
for individuals who cannot afford these high-cost medica-
tions [21]. By 2016, an estimated $US180–190 billion (i.e.,
15–16 %) savings for patients, payers, drug wholesalers,
and distributors will be achieved through discounts and
rebates on brand name medications [8].
2.2 Drug Distribution Networks and Channels
2.2.1 Specialty Pharmacies
Specialty pharmacies combine medication dispensing with
clinical disease management. Their services have been
used to improve patient outcomes and contain costs of
specialty pharmaceuticals [4]. These may be part of inde-
pendent pharmacy businesses, retail pharmacy chains,
wholesalers, pharmacy benefit managers (PBMs), or health
insurance companies. Over the last several years, payers
have been transitioning to obligate beneficiaries to receive
self-administered agents (SAAs) from contracted specialty
pharmacies, limiting the choice of acceptable specialty
pharmacy providers (SPPs) for patient services [3, 19, 22].
Benefits from more restricted specialty networks include
more cost-effective pricing and less variability in patient
care and experience [3, 4]. Specialty pharmacies manage
the complex reimbursement process, with the goal of
making it easier for patients, providers, and payers. PBMs
can reject filling or covering a specialty pharmaceutical
product if is it not dispensed through its preferred SPP.
These entities provide cost-management services, includ-
ing contracting with pharmaceutical manufacturers for
discounted pricing and assisting patients to obtain PAs [4].
Payer organizations can receive medication rebates directly
through contracting with specific specialty vendors or
through PBMs. These rebates create cost savings and are
typically available for specialty pharmaceutical classes
with higher utilization, such as those agents for rheumatoid
arthritis and MS as well as growth hormones [3, 23].
Specialty pharmacies also help payers control drug costs by
only providing medications for individuals who meet reg-
ulated indications for these high-cost drugs [21].
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Additional clinical services include educating patients
and their caregivers about drug administration and han-
dling, as well as monitoring for potential adverse effects,
drug interactions, and patient adherence. However, there is
also some concern about fragmented care, since the spe-
cialty pharmacy may not be part of a multidisciplinary
team within the clinical care setting with access to relevant
patient information. An increased use of electronic health
records may mitigate this issue. Specialty pharmacies also
frequently have mechanisms to provide refill reminders and
clinical status follow-ups. Specialty pharmacies frequently
provide mail-order home delivery; some offer distribution
via community pharmacies [24].
The National Comprehensive Cancer Network (NCCN)
Task Force expressed concern for the integrity of medi-
cations that require sterile compounding by the pharmacists
and subsequent delivery to the patient or physician. With
these distribution mechanisms, it is difficult to verify the
chain of custody and appropriate storage of the com-
pounded medications. Hematologic, renal, and hepatic
function are frequently tested immediately prior to drug
administration in oncology clinics. If the medication has
been prepared by the compounding pharmacy prior to test
results being reported, cancellation of treatment or dose
modification based on these laboratory tests may result in
waste. Thus, unused compounded medication may mean
that a mechanism designed to control costs may adversely
impact potential savings. Health system pharmacies (i.e.,
inpatient hospital pharmacies and outpatient clinic phar-
macies) are also disturbed by the loss of revenue with the
specialty pharmacy distribution model, since the health
system will receive reimbursement for administration of
the product, but not for dispensing of the product itself [24,
25].
2.3 Medication Therapy Management
and Coordination of Care
Legislation in the Medicare Prescription Drug, Improve-
ment, and Modernization Act of 2003 mandated to provide
medication therapy management (MTM) services for
individuals with multiple chronic diseases who are taking
multiple medications. According to CMS guidance docu-
ments for 2013, reimbursable MTM services provided by
Medicare Part D sponsors must meet the following con-
ditions for beneficiaries: (1) a minimum of two or three
chronic disease states, (2) taking a minimum of two to
eight medications, and (3) likely to incur C$US3,144 in
annual costs for Part D drugs [26].
Several publications document MTM services in oncol-
ogy. MTM services correlate to improvements in patients’
understanding of medication indications, therapeutic goals,
and appropriate and safe medication use by identifying
patient-specific drug-related problems (DRPs). Pharmacists
play a critical role with direct patient interactions, coordi-
nating care, and ensuring accurate prescribing and dis-
pensing practices through implementation of health
information technology (HIT) improvements, such as
electronic order-entry systems [25, 27]. Large oncology
practices, which constitute about 40 % of US oncologists,
are increasingly looking to incorporate oncology pharma-
cists to ensure protocol compliance, accurate dose adjust-
ments, a heightened level of awareness for drug–drug
interactions, and opportunities for cost savings. For exam-
ple, by employing an oncology pharmacist and pharmacy
technician, oncology centers have been able to prepare and
administer intravenous immunoglobulin (IVIG) doses at the
center compared with costs of $US1,000 for purchasing
ready-to-administer IVIG or sending patients to an outpa-
tient hospital setting [28, 29]. Additional opportunities for
cost savings by employing an oncology pharmacist include
accurate tracking of medication use and maintenance of
inventory. Oncology pharmacists also work closely with
patients to provide medication refills and appropriate
medication counseling, as well as assisting patients with
obtaining free or low-cost medications and taking advan-
tage of patient-assistance programs typically offered
through drug manufacturers. Pharmacist MTM services are
reimbursable through Current Procedural Terminology
(CPT) codes identified by Medicare Part D [29].
Implementation of specialty pharmacy centers and
MTM practices to improve medication adherence, reduce
adherence barriers, create personalized care plans, and
implement cost-savings mechanisms are crucial to not only
the field of oncology, but also other disease states treated
with specialty drugs, such as MS and HIV. In a study
assessing the effectiveness of specialty pharmacy man-
agement services on patient adherence to MS medications,
medication adherence for the study population was
approximately 60 % compared with 2011 drug trend data
showing a 33 % adherence rate to MS therapy. The
adherent group in this study had fewer MS-related emer-
gency room visits and lower medical costs than the non-
adherent group [30]. Studies of pharmacist MTM programs
in both community pharmacy and HIV specialty practice
settings have demonstrated improved patient adherence,
with significantly better patient outcomes, such as reduced
viral loads and rising CD4? T-lymphocyte counts [30–33].
However, the total mean annual healthcare cost per patient
was 10 % higher for patients using the MTM community
pharmacy services. This was related to additional use of
non-HIV antiretroviral therapies (ART) and mental health
medical care [33]. Long-term benefits were not evaluated
in these studies.
Health institutions and payers are also developing
positions for clinical specialists to implement and monitor
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appropriate clinical drug use, correlating to optimization of
drug spend. Advocate Physicians Partners (APP) is a part
of the Advocate Health System across Chicago and central
Illinois, and is characterized as a hybrid model comprising
a physician health organization (PHO), MCO, and an
accountable care organization (ACO). In order to control
pharmacy expenditure and ensure the adherence to evi-
dence-based protocols that have increased less than 3 % in
per-member-per-month (PMPM) expenses over 2012, APP
created an oncology clinical pharmacist position. This
clinical pharmacist was responsible for maintaining speci-
alty/oncology-related protocols, measuring and promoting
compliance with protocols, and developing tools and edu-
cational resources for physicians, staff, and patients.
Incorporated into clinical pathway protocols were PAs,
where the physicians needed to identify the indication for
drug use prior to approval, dispensing, and administration
of the drug. To enhance protocol compliance, the oncology
clinical pharmacist created communication programs tar-
geting under-compliance with protocols specifically tar-
geting the staff with under-utilization of designated
protocols. A protocol compliance report was generated
quarterly. Prior to this implementation, the protocol com-
pliance was 62 %. However, after the clinical pharmacist
implemented programs to educate physicians and nurses
about the appropriate clinical and economic outcomes
associated with protocol compliance, the value increased to
100 %. Physicians were now notifying the pharmacy of
appropriate indications for specific medication utilization
compared with general chemotherapy protocols that were
previously being used. Due to clinical pharmacist inter-
ventions and increased protocol compliance by physicians,
the organization benefited from enhanced clinical educa-
tion and improved medication utilizations related to diag-
noses, thus minimizing an increase in drug expenditures
[34].
2.4 Accountable Care Organizations
ACOs have been implemented across the US as part of
healthcare reform through the Patient Protection and
Affordable Care Act (PPACA) of 2010. The ACO model
creates a new healthcare delivery and payment model
focused on value-based pricing and reimbursement as well
as on expanding the bundling of payments and use of
medical homes. Healthcare reform aims to improve quality
and efficiency of care, particularly at the current time
where overall healthcare costs account for 23 % of the US
federal budget. With ACOs paying closer attention to the
cost of care, there will be greater scrutiny to determine
coverage of specialty pharmaceuticals due to their high
acquisition costs. For shared savings reimbursement from
CMS, Medicare ACOs must meet certain thresholds for 33
quality standards that aim to provide better care for indi-
viduals and better health for populations. Shared savings
and losses through CMS are determined based on the dif-
ference between fee-for-service spending for a defined year
for the covered population of an ACO and a risk-adjusted
benchmark determined by estimated Medicare Part A and
Part B expenditures that would have occurred without the
ACO in place. The risk-adjusted benchmark is estimated
based on Part A and Part B spending historically over the
previous 3 years. Based on these incentives for improving
quality of care, while also reducing costs, it may impact the
choice of preferred specialty pharmaceuticals. ACOs are
assessing the overall value and benefit of therapeutic
interventions to patient outcomes, both clinically and
financially, in order to provide coverage for high-cost
specialty drugs when medically appropriate. According to
two established ACO models, Geisinger Health System and
Kaiser Permanente, success has been achieved by linking
patient care to gatekeeper physicians within an organiza-
tion in addition to incentives that reward cost-effective,
conscientious, and timely care. After more experience and
release of data for the ACO model in regards to cost-
effective utilization of specialty pharmaceuticals, future
management strategies may have a significant impact for
these high-cost medications [35].
2.5 Evidence-Based Medicine
The use of comparative effectiveness reviews has also
increased, and involves a population-based analysis to help
determine and assess evidence linked to the effectiveness,
benefits, and harms of different treatment options. This
heightened focus over the last several years is supported by
the US federal implementation of the Patient-Centered
Outcomes Research Institute (PCORI), which was created
by the PPACA of 2010. The PPACA launch of the PCORI
establishes an organization aimed at providing the best
obtainable evidence to optimize healthcare decisions and
outcomes. PCORI provides several opportunities for
research funding, which can support effectiveness research
of specialty pharmaceuticals, which can be quite difficult
and costly, especially when comparing outcomes between
agents. The use of comparative effectiveness research
(CER) by health insurance plans has increased over the last
several years. Medicare Part D and commercial plans may
consider CER, but it is not permitted to be utilized by
Medicare Part B. The use of CER and other outcomes-
based research studies have allowed companies to imple-
ment more appropriate cost-control mechanisms compared
with only utilizing clinical efficacy and safety data for
medications. The application and value of CER and out-
comes-based research will increase over the next several
years [4, 8].
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Many countries use CER in their decision making. Some
examples of agencies that provide guidance regarding use
of drugs and devices are the National Institute for Health
and Care Excellence (NICE) in the UK, the Haute Au-
thorite de Sante (HAS) in France, the Pharmaceutical
Benefits Scheme (PBS) in Australia, and the Institut fur
Qualitat und Wirtschaftlichkeit im Gesundheitswesen
(IQWiG) in Germany [36]. In addition to evaluating clin-
ical-effectiveness data, consideration of cost-effectiveness
analysis and budgetary impacts are part of these agencies’
mandates. Every National Health Service (NHS) patient in
the UK has the right to NICE-recommended therapies,
although access to the required companion molecular
diagnostic testing and lack of referrals to experts limits the
use of the approved treatments [37]. Since 2007, NICE has
recommended 31 % of the new medications it has
reviewed. Within the field of oncology, NICE recom-
mended, with no or minor restrictions, 52 % of therapies it
reviewed over its first 10 years of operations (1999–2008)
[38]. Rejection rates for oncology therapies have risen to
65 % since 2009. Cost effectiveness has been the most
frequent reason for rejection. NICE considers a cost of
£30,000 to be satisfactory for each quality-adjusted life-
year (QALY), a measure of disease-burden that takes into
account both the quality and the quantity of life. The
proposed pricing structure of some rejected medications
can be reconsidered in order to obtain NICE endorsement.
In addition, the UK has a temporary Cancer Drug Fund of
£200 million per annum to provide access for patients who
need treatment for their malignancies with NICE-rejected
therapies. This fund is set to expire in 2016 [39, 40].
2.6 Role of Biosimilars
The Biologics Price Competition and Innovation Act
(BPCIA) of 2009 authorized the US FDA to provide an
approval pathway for biologics that are ‘biosimilar’ to a
reference product while providing 12 years of market
exclusivity for the original branded biologic product. The
BPCIA also provides for potential of ‘interchangeability.’
Biosimilarity is defined as the product being ‘‘highly sim-
ilar to the reference product notwithstanding minor
differences in clinically inactive components.’’ Inter-
changeability is a higher standard. It is defined as the
product being able to ‘‘produce the same clinical result as
the reference product in any given patient and, if the bio-
logical product is administered more than once to an
individual, the risk in terms of safety or diminished effi-
cacy or alternating or switching between the use of the
biological product and the reference product is not greater
than the risk of using the reference product without such
alteration or switch’’ [41]. This bill allows a pharmacist to
make substitutions of products with similar reference
therapeutic products as designated by the FDA. The FDA
published draft guidance providing direction on scientific
and quality considerations to demonstrate biosimilarity and
addresses questions in relation to the BPCIA [42].
Lessons can be learned from the uptake of biosimilars in
Europe. The EU introduced biosimilar legislation in 2004
along with the European Medicines Agency (EMA) issuing
a class-specific guidance for several traditional and spe-
cialty pharmaceuticals: insulin, human growth hormone
(HGH), granulocyte colony-stimulating factors (G-CSFs),
erythropoietins, interferons, low-molecular-weight hepa-
rins, monoclonal antibodies (mAbs). European biosimilars
became available in 2007. Sixteen biosimilar products were
approved in the EU for HGH and growth factors [43]. In
July 2013, The EMA’s Committee for Medicinal Products
for Human Use (CHMP) recommended marketing autho-
rizations for the first two mAb biosimilars. RemsimaTM and
InflectraTM were deemed similar to the reference product,
infliximab (RemicadeTM), a chimeric mAb [44]. No sig-
nificant safety issues have been attributed to biosimilars for
EU products. However, the EMA advised against an
automatic substitution policy, and the agency requires
biosimilar manufacturers to implement risk management
programs (RMPs). This RMP requirement may provide
mixed messages to physicians about potential safety issues
[45]. Uptake for biosimilar prescribing has been relatively
slow in Europe despite price reductions of 14–35 % rela-
tive to the originator’s prices due to the reluctance of
physicians for biosimilar prescribing [46]. Nevertheless,
European sales of one product, ZarzioTM, a biosimilar fil-
grastim product, have exceeded those of the reference
product, NeupogenTM [47]. Cost-effectiveness has been
demonstrated for ZarzioTM for prophylaxis or treatment of
febrile neutropenia compared to NeupogenTM and its long-
acting counterpart, pegfilgrastim (Neulasta), across five
European countries [48]. If there were a significant shift
toward greater use of biosimilar products, as patents for
biologic products with global sales of $US100 billion
expire by 2020, substantial savings would be available for
patients and payers. However, it is unrealistic to project a
change in market share similar to that seen with small-
molecule generic products [49].
2.7 Government Pricing Controls
There is limited uptake of government pricing controls for
pharmaceuticals and biopharmaceuticals in the US com-
pared to the EU, primarily due to differences in the funding
and structure of the healthcare systems. On 4 February
2013, the Patient’s Access to Treatment Act (PATA) of
2013 was introduced in the House of Representatives with
the plan to limit cost sharing of specialty tier drugs to the
level of non-preferred brand tiers. If plans have more than
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one non-preferred tier, the specialty tier drug’s cost sharing
will be limited to the tier with lower cost sharing for en-
rollees. Additionally, this proposed law would require no
more than a 10 % difference in total cost-sharing expense
for any drugs on a particular tier [50, 51].
Avalere Health, an advisory group focused on solving
challenges facing the healthcare industry, estimated the
impact of US legislation, PATA (H.R. 460), on commercial
health plan premiums and cost-sharing strategies. It was
estimated that there would be an approximately $US3.00
annual increase in premiums for individuals on plans with a
specialty tier as well as a negligible $US0.37 average
annual increase for those plans with a co-payment model
and a $US7.78 average annual increase for those plans that
implement co-insurance. Avalere Health concluded that the
overall cost burden to commercial enrollees due to H.R.
460 will be minimal [52, 53]. Since the utilization of
specialty pharmaceuticals is relatively inelastic, decreases
in cost sharing for these medications will result in an
estimated 3 % increase in specialty drug spend [54].
3 Looking Forward: The Future and Identification
of Gaps in Specialty Pharmaceutical Cost
Management
On a global scale, there will continue to be a rise in spe-
cialty pharmaceutical penetration of the market, with
between 600 and 1,000 specialty drugs in the global
pipeline according to Chief Financial Officer Jeffrey L.
Hall at the UBS Global Healthcare Conference. Global
spending on medicines will grow to nearly $US1.2 trillion
by 2016, with emerging markets, contributing to a greater
share of spending, particularly for biologics, and generic
medications. Of this spending, an estimated $US200–210
billion is expected for spending on biologic medications,
with $US4–6 billion (2 % of biologic spending) toward
biosimilars [7, 35–57].
In the US, forecasts indicate that specialty drug spend
will increase about 20 % annually and consume 40 % of
the drug budget by 2016. Across the US healthcare
industry, there are growing concerns about the high costs of
specialty drugs. Changes in prescription benefit design, and
utilization of cost-management strategies, will continue to
evolve in order to ensure value-based healthcare decisions
for specialty pharmaceuticals [13]. However, gaps in data
exist regarding the utilization and cost management of
specialty pharmaceuticals, particularly on a global scale.
Specialty pharmaceuticals are a rapidly growing and
dynamic component of the healthcare industry and phar-
maceutical market; with this comes greater clinical utili-
zation as well as increased costs. Since significant
differences exist between traditional pharmaceuticals and
specialty pharmaceuticals, all involved stakeholders,
including payers and providers, have adjusted current
techniques and implemented innovative strategies to ensure
appropriate drug utilization and management. However,
these trends have evolved over the last decade and will
continue to progress with advances in specialty pharma-
ceutical development and utilization as well as healthcare
reform practices.
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